The market for weight-loss treatments is expected to see 16 new drugs vying for a slice of the lucrative business currently dominated by Novo Nordisk, and Eli Lilly, according to estimates from analysts at Morningstar and Pitchbook.

In a joint report published on Monday (Sept 9), analysts estimated the market for obesity treatments could expand to US$200 billion (S$260 billion) by 2031. The 16 drugs could launch by 2029, with roughly US$70 billion of the GLP-1 market coming from these new challengers.

Related

---